Related Experiment Video
Updated: Jan 6, 2026
06:17
Expression and Purification of Virus-like Particles for Vaccination
Published on: June 2, 2016
22.7K
BLV: lessons on vaccine development
Alejandro Abdala1, Irene Alvarez2, Hélène Brossel3
1Estacion Experimental Agropecuaria Rafaela, INTA, 2300, Rafaela, Argentina.
Retrovirology
|October 9, 2019
Summary
Developing effective vaccines against retroviruses like bovine leukemia virus (BLV) is difficult due to viral latency and integration. This review examines challenges and strategies for creating safe and effective BLV vaccines.
Area of Science:
- Veterinary immunology
- Retroviral vaccine development
- Bovine leukemia virus (BLV) research
Background:
- Retroviruses, including BLV, pose vaccination challenges due to genomic integration and immune evasion.
- Established BLV infections are difficult to clear, necessitating sterilizing immunity through vaccination.
- Vaccine-associated risks include increased infection susceptibility and pathogen reversion.
Purpose of the Study:
- To review the challenges in developing an efficient vaccine against bovine leukemia virus (BLV).
- To analyze historical vaccine failures and current vaccine candidate efficacy and safety.
- To discuss economic factors influencing industrial vaccine development.
Main Methods:
- Review of historical data on inactivated BLV vaccines.
- Evaluation of efficacy and safety studies on live-attenuated BLV vaccine candidates.
- Analysis of economic feasibility for large-scale vaccine production.
Main Results:
- Inactivated BLV vaccines have historically failed to provide adequate protection.
- Live-attenuated vaccines show promise in terms of efficacy and safety but face development hurdles.
- Economic constraints significantly impact the industrialization of new BLV vaccines.
Conclusions:
- Developing a successful BLV vaccine requires overcoming challenges related to viral latency and immune escape.
- Live-attenuated vaccines represent a potential strategy, but further research and development are crucial.
- Economic viability is a critical consideration for the successful commercialization of BLV vaccines.
More Related Videos
05:15Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
Published on: February 10, 2022
4.1K
08:27Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
Published on: August 13, 2021
5.0K
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
905
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
905
01:28Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
01:51Vaccinations
51.1K
Overview
51.1K
01:22Development of Immunocompetence
745
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
745
01:30Cancer Vaccines
913
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
913
01:11Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K